Elan Assembles Antegren Team; Hires Four Execs Ahead Of FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Serono’s former Rebif clinical development head Gordon Francis, MD, is named Elan VP-neurology. Elan also announces appointments in manufacturing/supply, reimbursement and sales & marketing.
You may also be interested in...
Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End
Biogen Idec and Elan are requesting priority review for the MS submission. Companies are also seeking accelerated approval; BLA is based on one-year data from ongoing AFFIRM and SENTINEL trials.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?